Merz Neurosciences Announces Data Presentations At The 9th World Congress For Neurorehabilitation

RALEIGH, N.C.--(BUSINESS WIRE)--Merz Neurosciences, a division of Merz North America (US affiliate of the global Merz Pharma Group), today announced that Merz has two oral presentations at the 9th World Congress for Neurorehabilitation in Philadelphia, PA, including data for XEOMIN® (incobotulinumtoxinA) in the treatment of adult Upper Limb Spasticity (ULS), the indication for which Merz recently received FDA approval.